IS5375A - KAY-nýstárlegt ónæmisprótín - Google Patents

KAY-nýstárlegt ónæmisprótín

Info

Publication number
IS5375A
IS5375A IS5375A IS5375A IS5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A
Authority
IS
Iceland
Prior art keywords
kay
innovative
immune protein
immune
protein
Prior art date
Application number
IS5375A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of IS5375A publication Critical patent/IS5375A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS5375A 1997-09-12 2000-02-11 KAY-nýstárlegt ónæmisprótín IS5375A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
IS5375A true IS5375A (is) 2000-02-11

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5375A IS5375A (is) 1997-09-12 2000-02-11 KAY-nýstárlegt ónæmisprótín

Country Status (17)

Country Link
EP (1) EP1012270A2 (is)
JP (1) JP2001515711A (is)
KR (1) KR20010023892A (is)
CN (1) CN1269832A (is)
AU (1) AU9315298A (is)
BR (1) BR9812433A (is)
CA (1) CA2303424A1 (is)
EA (1) EA200000311A1 (is)
EE (1) EE200000148A (is)
HU (1) HUP0004034A3 (is)
IL (1) IL134480A0 (is)
IS (1) IS5375A (is)
NO (1) NO20001240L (is)
PL (1) PL339740A1 (is)
SK (1) SK3532000A3 (is)
TR (1) TR200000654T2 (is)
WO (1) WO1999012964A2 (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JP2002503444A (ja) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2319527A3 (en) * 1999-01-25 2011-10-12 Biogen Idec MA Inc. BAFF, inhibitors thereof and their use in the modulation of the B-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
DK1210425T4 (en) 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
EP1255558B1 (en) 2000-02-16 2006-06-14 Genentech, Inc. Anti-april antibodies and hybridoma cells
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN1970077A (zh) 2001-05-11 2007-05-30 安姆根有限公司 与tall－1结合的肽和相关分子
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
JP5524441B2 (ja) 2003-03-28 2014-06-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド 短縮されたｂａｆｆレセプター
MXPA05013117A (es) 2003-06-05 2006-03-17 Genentech Inc Terapia de combinacion para trastornos de celulas-b.
EP1675609A1 (en) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Therapeutic regimens for baff antagonists
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20060110387A1 (en) 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2007249223B2 (en) 2006-05-15 2012-08-02 Ares Trading S.A. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
EP2680884B1 (en) 2011-02-28 2018-01-17 F. Hoffmann-La Roche AG Biological markers and methods for predicting response to b-cell antagonists
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
BR9612752A (pt) * 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
WO1999012964A3 (en) 1999-05-27
CA2303424A1 (en) 1999-03-18
TR200000654T2 (tr) 2000-07-21
SK3532000A3 (en) 2001-12-03
JP2001515711A (ja) 2001-09-25
CN1269832A (zh) 2000-10-11
EA200000311A1 (ru) 2000-10-30
AU9315298A (en) 1999-03-29
NO20001240L (no) 2000-05-10
PL339740A1 (en) 2001-01-02
EP1012270A2 (en) 2000-06-28
NO20001240D0 (no) 2000-03-09
HUP0004034A3 (en) 2002-08-28
EE200000148A (et) 2001-02-15
WO1999012964A2 (en) 1999-03-18
BR9812433A (pt) 2000-09-26
IL134480A0 (en) 2001-04-30
KR20010023892A (ko) 2001-03-26
HUP0004034A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
IS5375A (is) KAY-nýstárlegt ónæmisprótín
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
DE69839603D1 (de) Zierenden proteins
NO20002990L (no) Nytt overflateprotein
ID24289A (id) Benzotiazol inhibitor-inhibitor protein terosin kinase
DE69828330D1 (de) Aktiviertes Protein C Formulierungen
NO983364L (no) Konsensusproteiner
NO2010013I2 (no) Rekombinant FSH-CTP
DE69826554D1 (de) Lehnstuhl
DE69805844T2 (de) Ifnnar/ifn komplex
DE69836069D1 (de) Zweirichtungsthyristor
ATE295417T1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
DK0862850T3 (da) Mejetærsker
DE29720457U1 (de) Besteckteil
DE69830081D1 (de) Zwischenstück
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
DE29719589U1 (de) Vereinzelner
ID23663A (id) Persiapan kaprolaktam
DE29701686U1 (de) Interface
DE29707538U1 (de) Nahrungsmittel
KR980000586U (ko) 수저통
DE29711001U1 (de) Bodenfreier Beschlag
DE29723950U1 (de) Fördervorrichtung
ITMI972543A0 (it) Proteina p27bbp